Phase 1b Combo w/ Ribociclib and Alpelisib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer|HR-positive Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: OP-1250|DRUG: Ribociclib|DRUG: Alpelisib
Sponsor: Olema Pharmaceuticals, Inc.
Collaborators: Novartis